ALK-Abello A/S (ALKb.CO)
19 Mar 2018
* Q4 TOTAL REVENUE DKK 763 MILLION (REUTERS POLL: DKK 771 MILLION)
* PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S
* ALK-ABELLÓ A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Danish pharma company Alk Abello said on Monday it would invest 1 billion Danish crowns ($159 million) in its North America business, a move that is expected put a lid on earnings and revenue growth in the near term.
Dec 4 Danish pharma company Alk Abello said on Monday it would invest about 1 billion Danish crowns ($159.5 million) over the next three years to develop its North America business and said it expected earnings to be subdued during this period.
* WILL INVEST APPROXIMATELY DKK 1 BILLION TO SUCCEED IN NORTH AMERICA
* ALK SECURES PRICING AND REIMBURSEMENT FOR ACARIZAX® IN FRANCE
* Q3 TOTAL REVENUE DKK 667 MILLION VERSUS DKK 630 MILLION YEAR AGO
* HE IS EXPECTED TO TAKE UP HIS NEW ROLE BY 2 JANUARY 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-ALK-Abello says Jupiter Asset Management reduced ownership in ALK to below 5 pct of share capital
* Received notification from Jupiter Asset Management, that Jupiter reduced ownership in ALK to below 5% of share capital Source text for Eikon: Further company coverage: